Clinical Trial Update: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating pembrolizumab with or without chemotherapy in advanced esophageal squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Chemotherapy regimens (unspecified)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 1, Phase 2 | Status: COMPLETED